Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

被引：1

作者：

Johnson, Nathalie A. ^{[1
]}

Lavie, David ^{[2
]}

Borchmann, Peter ^{[3
]}

Gregory, Gareth P. ^{[4
]}

Herrera, Alex F. ^{[5
]}

Minuk, Leonard ^{[6
,7
]}

Vucinic, Vladan ^{[8
]}

Armand, Philippe ^{[9
]}

Avigdor, Abraham ^{[10
]}

Gasiorowski, Robin ^{[11
]}

Herishanu, Yair ^{[12
]}

Keane, Colm ^{[13
]}

Kuruvilla, John ^{[14
]}

Palcza, John ^{[15
]}

Pillai, Pallavi ^{[15
]}

Nahar, Akash ^{[15
]}

Timmerman, John ^{[16
]}

机构：

[1] Jewish Gen Hosp, Montreal, PQ, Canada

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Univ Klinikum Koeln AOER, Cologne, Germany

[4] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia

[5] City Hope Natl Med Ctr, Duarte, CA USA

[6] CancerCare Manitoba, Winnipeg, MB, Canada

[7] Univ Manitoba, Winnipeg, MB, Canada

[8] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Chaim Sheba Med Ctr, Ramat Gan, Israel

[11] Univ Sydney, Concord Hosp, Concord, Australia

[12] Sourasky Med Ctr, Tel Aviv, Israel

[13] Princess Alexandra Hosp, Brisbane, Qld, Australia

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166846

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6540 / 6542

页数：3

共 50 条

[21] Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Diefenbach, Catherine S.
Hong, Fangxin
Ambinder, Richard F.
Cohen, Jonathan B.
Robertson, Michael J.
David, Kevin A.
Advani, Ranjana H.
Fenske, Timothy S.
Barta, Stefan K.
Palmisiano, Neil D.
Svoboda, Jakob
Morgan, David S.
Karmali, Reem
Sharon, Elad
Streicher, Howard
Kahl, Brad S.
Ansell, Stephen M.
LANCET HAEMATOLOGY, 2020, 7 (09): : E660 - E670
[22] A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
Wang, H-Y
Wu, S-G
Lin, Y-T
Chen, C-Y
Shih, J-Y
ESMO OPEN, 2022, 7 (06)
[23] Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Locatelli, Franco
Mauz-Koerholz, Christine
Neville, Kathleen
Llort, Anna
Beishuizen, Auke
Daw, Stephen
Pillon, Marta
Aladjidi, Nathalie
Klingebiel, Thomas
Landman-Parker, Judith
Medina-Sanson, Aurora
August, Keith
Sachs, Jessica
Hoffman, Kristen
Kinley, Judith
Song, Sam
Song, Gregory
Zhang, Stephen
Suri, Ajit
Gore, Lia
LANCET HAEMATOLOGY, 2018, 5 (10): : E450 - E461
[24] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Lin, Chia-Chi
Garralda, Elena
Schoeffski, Patrick
Hong, David S.
Siu, Lillian L.
Martin, Miguel
Maur, Michela
Hui, Rina
Soo, Ross A.
Chiu, Joanne
Zhang, Tian
Ma, Brigette
Kyi, Chrisann
Tan, Daniel S. W.
Cassier, Philippe A.
Sarantopoulos, John
Weickhardt, Andrew
Carvajal, Richard D.
Spratlin, Jennifer
Esaki, Taito
Rolland, Frederic
Akerley, Wallace
Deschler-Baier, Barbara
Rispoli, Lawrence
Samant, Tanay S.
Chowdhury, Niladri Roy
Gusenleitner, Daniel
Kwak, Eunice L.
Askoxylakis, Vasileios
De Braud, Filippo
ONCOIMMUNOLOGY, 2024, 13 (01):
[25] A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Fehniger, Todd A.
Larson, Sarah
Trinkaus, Kathryn
Siegel, Marilyn J.
Cashen, Amanda F.
Blum, Kristie A.
Fenske, Timothy S.
Hurd, David D.
Goy, Andre
Schneider, Stephanie E.
Keppel, Catherine R.
Wagner-Johnston, Nina D.
Carson, Kenneth R.
Bartlett, Nancy L.
BLOOD, 2011, 118 (19) : 5119 - 5125
[26] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
Johnston, P. B.
Lewis, L. T.
Rogerio, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study (vol 22, pg 512, 2021)
Kuruvilla, J.
Ramchandren, R.
Santoro, A.
LANCET ONCOLOGY, 2021, 22 (05): : E184 - E184
[28] Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
Rha, Sun Young
Miller, Wilson H.
de Miguel, Maria Jose
Im, Seock-Ah
Lugowska, Iwona
Wermke, Martin
Kotani, Daisuke
Bauer, Todd Michael
Takashima, Atsuo
Palcza, John
Chaney, Marya F.
Dobrenkov, Konstantin
Garralda, Elena
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 394 - 394
[29] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
Laubach, Jacob P.
Tuchman, Sascha A.
Rosenblatt, Jacalyn M.
Mitsiades, Constantine S.
Colson, Kathleen
Masone, Kelly
Warren, Diane
Redd, Robert A.
Grayson, Dena
Richardson, Paul G.
BLOOD CANCER JOURNAL, 2021, 11 (02)
[30] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase 2 Study
Martin, Peter
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 6 - 7

← 1 2 3 4 5 →